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HIV RepoRts
Background: Sexually transmitted infections (STIs) in pregnancy such as 
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) may lead to 
adverse infant outcomes.
Methods: Individual urine specimens from HIV-infected pregnant 
women diagnosed with HIV during labor were collected at the time of 
infant birth and tested by polymerase chain reaction for CT and NG. 
Infant HIV infection was determined at 3 months with morbidity/mortal-
ity assessed through 6 months.
Results: Of 1373 maternal urine samples, 277 (20.2%) were positive for CT 
and/or NG; 249 (18.1%) for CT, 63 (4.6%) for NG and 35 (2.5%) for both CT 
and NG. HIV infection was diagnosed in 117 (8.5%) infants. Highest rates 
of adverse outcomes (sepsis, pneumonia, congenital syphilis, septic arthritis, 
conjunctivitis, low birth weight, preterm delivery and death) were noted in 
infants of women with CT and NG (23/35, 65.7%) compared with NG (16/28, 
57.1%), CT (84/214, 39.3%) and no STI (405/1096, 37%, P = 0.001). Death 
(11.4% vs. 3%, P = 0.02), low birth weight (42.9% vs. 16.9%, P = 0.001) and 
preterm delivery (28.6% vs. 10.2%, P = 0.008) were higher among infants of 
CT and NG-coinfected women. Infants who had any adverse outcome and 
were born to women with CT and/or NG were 3.5 times more likely to be 
HIV infected after controlling for maternal syphilis (odds ratio: 3.5, 95% con-
fidence interval: 1.4–8.3). By adjusted multivariate logistic regression, infants 
born to mothers with any CT and/or NG were 1.35 times more likely to have 
an adverse outcome (odds ratio, 1.35; 95% confidence interval, 1.03–1.76).
Conclusions: STIs in HIV-infected pregnant women are associated with 
adverse outcomes in HIV-exposed infected and uninfected infants.
Key Words: HIV, pregnancy, chlamydia, gonorrhea, sexually transmitted 
infections, adverse infant outcomes
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Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
ISSN: 0891-3668/16/3508-0894
DOI: 10.1097/INF.0000000000001199
Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-infected 
Pregnant Women and Adverse Infant Outcomes
Kristina Adachi, MD,* Jeffrey D. Klausner, MD, MPH,*† Jiahong Xu, MS, MPH,‡ Bonnie Ank, BA,*  
Claire C. Bristow, PhD, MPH, MSc,† Mariza G. Morgado, PhD,§ D. Heather Watts, MD,¶ Fred Weir, PhD,║  
David Persing, MD, PhD,║ Lynne M. Mofenson, MD,** Valdilea G. Veloso, MD,§ Jose Henrique Pilotto, MD,††  
Esau Joao, MD,‡‡ Glenda Gray, MD,§§ Gerhard Theron, MD,¶¶ Breno Santos, MD,║║ Rosana Fonseca, MD,*** 
Regis Kreitchmann, MD,††† Jorge Pinto, MD,‡‡‡ Marisa M. Mussi-Pinhata, MD,§§§ Mariana Ceriotto, MD,¶¶¶  
Daisy Maria Machado, MD,║║║ Yvonne J. Bryson, MD,* Beatriz Grinsztejn, MD, PhD,§ Francisco I. Bastos, MD, PhD,§ 
George Siberry, MD, MPH,** and Karin Nielsen-Saines, MD, MPH,* for the NICHD HPTN 040 Study Team
Accepted for publication January 22, 2016.
From the *David Geffen UCLA School of Medicine, Los Angeles, California; 
†UCLA Fielding School of Public Health, Department of Epidemiology, Los 
Angeles, California; ‡Westat, Rockville, Maryland; §Fundacao Oswaldo Cruz 
(FIOCRUZ), Rio de Janeiro, Brazil; ¶Office of the Global AIDS Coordinator, 
US Department of State, Washington DC; ║Cepheid, Sunnyvale, California; 
**Eunice Kennedy Shriver National Institute of Child Health and Human 
Development, National Institutes of Health, Bethesda, Maryland; ††Hospital 
Geral de Nova Iguaçu, DST/AIDS, Nova Iguaçu, Rio de Janeiro, Brazil; ‡‡Hos-
pital Federal dos Servidores do Estado, Rio de Janeiro, Brazil; §§SAMRC and 
Perinatal HIV Research Unit, University of Witwatersrand, Cape Town, South 
Africa; ¶¶Department of Obstetrics and Gynecology, Stellenbosch University/
Tygerberg Hospital, Cape Town, South Africa; ║║Serviço de Infectologia, Hos-
pital Conceicao, Porto Alegre, Rio Grande do Sul, Brazil; ***Hospital Femina, 
Porto Alegre, Rio Grande do Sul, Brazil; †††Irmandade da Santa Casa de Miseri-
cordia de Porto Alegre, Rio Grande do Sul, Brazil; ‡‡‡Department of Pediat-
rics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; 
§§§Department of Pediatrics, Ribeirão Preto Medical School, University of São 
Paulo, São Paulo, Brazil; ¶¶¶Foundation for Maternal and Infant Health (FUN-
DASAMIN), Buenos Aires, Argentina; and ║║║Escola Paulista de Medicina- 
Universidade Federal de São Paulo, São Paulo, Brazil.
Clinical Trials Registration Number: NCT00099359. 
Preliminary data were presented at the Pediatric Academic Societies Conference 
and Asian Society for Pediatric Research Joint Meeting in Vancouver, Can-
ada on May 5, 2014. Abstract number 754433. Preliminary data restricted 
to the Americas cohort were presented at the Centers for Disease Control 
and Prevention STD Prevention Conference in collaboration with the 15th 
International Union against Sexually Transmitted Infections (IUSTI) World 
Congress and 2nd Latin American International Union against Sexually 
Transmitted Infections (IUSTI-ALACITS) Congress in Atlanta, Georgia, 
US. on June 12, 2014. Abstract number 34402.
The NICHD HPTN 040 study was supported by NICHD Contract # 
HHSN267200800001C (NICHD Control # N01-HD-8-0001) and U01 
AI047986 (Brazilian AIDS Prevention Trials International Network), National 
Institute of Allergy and Infectious Diseases (NIAID)/NIH. Overall support for 
the International Maternal Pediatric Adolescent AIDS Clinical Trials Group 
(IMPAACT) was provided by the National Institute of Allergy and Infec-
tious Diseases (NIAID) of the National Institutes of Health (NIH) under 
Award Numbers NIAIDU01 AI068632, UM1AI068632 (IMPAACT LOC), 
UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), 
with co-funding from the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development (NICHD) and the National Institute of Men-
tal Health (NIMH (AI068632). In addition, the parent study was supported in 
part by Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), and GlaxoSmith-
Kline on behalf of ViiV Healthcare. The authors meet criteria for authorship 
as recommended by the International Committee of Medical Journal Editors 
(ICMJE) and were fully responsible for all aspects of manuscript development. 
This particular sub-study was supported by Cepheid, Sunnyvale, CA, where 
CT and NG testing of specimens was performed. Support was also provided by 
the UCLA Center for AIDS Research (CFAR) NIH/ NIAID AI028697. Sup-
port for Kristina Adachi's work on this sub-study was also provided in part by 
the UCLA Children's Discovery and Innovation Institute (CDI). The content, 
conclusions and opinions expressed in this article are those of the authors and 
do not necessarily represent those of the National Institutes of Health, the U.S. 
Department of Health and Human Services, or the U.S. Department of State, 
affiliated universities, programs or companies of the authors.
Fred Weir, PhD is the Director of Research and Development at Cepheid. David 
Persing MD, PhD is the Executive Vice President, Chief Medical & Technology 
Officer of Cepheid. The other authors have no conflicts of interest to disclose.
Change of Author Affiliations: Lynne Mofenson, MD has retired from service at 
the Eunice Kennedy Shriver National Institute of Child Health and Human 
Development, National Institutes of Health, Bethesda, MD. Claire C. Bris-
tow, PhD, MPH, MSc was previously at the UCLA Fielding School of Public 
Health but is now at UCSD School of Medicine, Division of Global Public 
Health. D. Heather Watts, MD and George Siberry, MD, MPH were previ-
ously at the Eunice Kennedy Shriver National Institute of Child Health and 
Human Development, National Institutes of Health, Bethesda, MD, U.S., but 
are currently at the Office of the Global AIDS Coordinator, U.S. Department 
of State, Washington D.C., U.S.
Address for correspondence: Kristina Adachi, MD, David Geffen School of 
Medicine at UCLA, Division of Infectious Diseases, Department of Pediat-
rics, 10833 Le Conte Ave, MDCC 22-442, Los Angeles, CA 90095. E-mail: 
kadachi@mednet.ucla.edu.
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
The Pediatric Infectious Disease Journal • Volume 35, Number 8, August 2016 CT, NG and Adverse Infant Outcomes
© 2016 Wolters Kluwer Health, Inc. All rights reserved. www.pidj.com | 895
In 2008, the World Health Organization estimated that 105.7 mil-lion new Chlamydia trachomatis (CT) and 106.1 million Neisse-
ria gonorrhoeae (NG) infections occurred worldwide, with highest 
rates in low- and middle-income countries.1 Sexually transmitted 
infections (STIs) including CT and NG pose additional health risks 
for HIV-infected pregnant women. Untreated chlamydial and gono-
coccal infections in pregnancy may lead to fetal loss, premature 
rupture of membranes and preterm labor and delivery.2–6 Maternal 
chlamydial infections may lead to neonatal conjunctivitis and pneu-
monia,4 whereas gonococcal infections may also predispose infants 
to conjunctivitis and in rare cases disseminated infections such as 
sepsis and septic arthritis.3
In response to limited published research from low- and 
middle-income countries of HIV-infected pregnant women with 
CT and/or NG infections, the present substudy aimed to assess the 
health of HIV-exposed infants in the first 6 months of life, par-
ticularly in association with these maternal STIs. We, therefore, 
evaluated adverse infant outcomes associated with these STIs dur-
ing pregnancy including sepsis, pneumonia, congenital syphilis, 
septic arthritis, conjunctivitis, death, low birth weight and prema-
ture delivery. In a separate report, we described the prevalence of 
STIs in the National Institute of Child Health and Human Develop-
ment HIV Prevention Trials Network (NICHD HPTN) 040 cohort 
and evaluated potential associations between maternal STIs and 
mother-to-child HIV transmission.7
MATERIALS AND METHODS
Study Design
This study was a substudy of the NICHD HPTN 040 trial, 
also known as International Maternal Pediatric Adolescent AIDS 
Clinical Trials Network (IMPAACT P1043) NICHD/HPTN 040 (or 
P1043), a phase 3, triple-arm, randomized, open-label, multicenter 
study that evaluated the efficacy, safety and tolerance of 3 differ-
ent infant antiretroviral prophylaxis regimens for the prevention 
of intrapartum HIV transmission to infants born to HIV-infected 
pregnant women, who had not received antiretroviral drugs during 
pregnancy.8
Study enrollment consisted of 1684 HIV-infected pregnant 
women diagnosed with HIV infection at the time of labor and deliv-
ery. All women provided written informed consent. Enrollment 
occurred at multiple sites in Brazil, South Africa, Argentina and the 
United States. Infants <32 weeks of gestational age were excluded 
from the study.
Maternal plasma HIV RNA levels and CD4+ T-lymphocyte 
subsets were obtained at the time of labor and delivery. Syphi-
lis testing was performed at the time of labor and delivery using 
Venereal Disease Research Laboratory test titers with confirma-
tory treponemal syphilis antibody tests, per standard of care. The 
primary endpoint of the parent study was HIV infection status at 
3 months of age. However, infants were followed until 6 months of 
age for safety and toxicity monitoring in the parent study. Adverse 
infant outcome data through age 6 months were collected, which 
included the variables of interest in this substudy: sepsis, pneumo-
nia, congenital syphilis, septic arthritis, conjunctivitis, death, low 
birth weight (<2500 g) and premature delivery (<37 weeks and 
≥32 weeks).
HIV Diagnosis
HIV DNA polymerase chain reaction (PCR) was performed 
on infants within 48 hours of birth and at 10–14 days, 4–6 weeks, 
3 months and 6 months of age. Repeat HIV DNA PCR testing was 
performed to confirm a positive result. Diagnosis of infant HIV 
infection required 2 positive HIV DNA PCR test (Roche Molecular 
Systems Inc., Basel, Switzerland) results collected on different 
days. During the primary study, infants with a positive HIV DNA 
PCR test result at birth and positive results on repeat testing were 
classified as having in utero HIV infection. Infants with a nega-
tive HIV DNA PCR result at birth and a positive HIV DNA PCR 
result on subsequent testing were classified as having intrapartum 
HIV infection. All HIV-exposed infants enrolled in the study were 
exclusively formula fed.
Specimen Collection and Chlamydia and 
Gonorrhea Testing
Stored maternal urine samples, 1 per patient, collected at the 
time of labor and delivery or within 48 hours of birth were frozen 
at −80°C and stored at study sites. Stored urine was thawed, and 
aliquots (7 mL each) were shipped on dry ice for testing at Cepheid, 
Sunnyvale, CA. Urine samples were tested for the presence of CT 
and NG using the Xpert CT/NG assay. Results were reported as 
positive, negative or indeterminate. Indeterminate test results were 
repeated up to 2 times, and those that remained indeterminate were 
excluded from data analysis.
Statistical Analysis
Chi-square (or Fisher exact) test was used to assess the dif-
ference in proportions of infants with adverse outcomes, including 
sepsis, pneumonia, congenital syphilis, septic arthritis, conjunctivi-
tis, death, low birth weight (<2500 g) and premature delivery (<37 
weeks), according to maternal STI status (only CT-infected, only 
NG-infected, CT and NG coinfected or CT and/or NG uninfected) 
and infant HIV status [HIV-infected (in utero and intrapartum) or 
HIV-uninfected], respectively. Univariate and multivariate logistic 
regression modeling (or exact logistic regression as necessary) was 
used to examine the relationship between adverse clinical outcome 
and infants born to women with CT and/or NG infection. All com-
putations were done using SAS software v9.3 (Cary, NC).
Human Subjects
Both the parent trial and the present analysis were approved 
by the institutional review boards and national ethics committees at 
each study site.
RESULTS
Urine samples from 1406 HIV-1-infected women were tested 
for CT and NG infections. After excluding 33 indeterminate results 
(2.3% of samples), 1373 maternal urine test results with linked 
infant outcomes (81.5% of the 1684 women enrolled in the original 
study) were included in the analysis. Women were from study sites 
in Brazil (68.3%), South Africa (29.8%), Argentina (1.4%) and the 
United States (0.5%). Further detail on the sociodemographics of 
our cohort was previously described in our earlier manuscript.7 For 
the 1373 HIV-infected pregnant women included, 249 (18.1%) had 
any CT, 63 (4.6%) any NG and 35 (2.5%) had both CT and NG; 
277 women (20.2%) were positive overall for CT and/or NG. One 
hundred seventeen (8.5%) infants were HIV infected including 75 
(64.1%) infants infected in utero and 42 (35.9%) infants infected 
intrapartum (Fig. 1).
Adverse Infant Outcomes and Maternal Chlamydia 
and Gonorrhea
Of 1373 infants, 528 (38.5%) had at least one of the fol-
lowing adverse outcomes (sepsis, pneumonia, congenital syphilis, 
septic arthritis, conjunctivitis, death, low birth weight or prema-
turity), and significant differences were noted among infants born 
to CT- and/or NG-infected women as compared with uninfected 
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women (P = 0.001). The highest rates of any of those adverse out-
comes were noted among infants born to women with both CT and 
NG (65.7%) when compared with those with NG only (57.1%), CT 
only (39.3%) and no STI (37%, P = 0.001; Table 1).
In the cohort, 41 (3.0%) infant deaths occurred, and differ-
ences in infant death rates were noted among those born to STI-
infected and STI-uninfected women (P = 0.02). Death rates were 
highest among infants born to women with CT and NG (11.4%) 
compared with those born to women with NG only (0%), CT only 
(1.9%) and CT- or NG-uninfected (3%) women.
Two hundred forty-four (17.8%) of the births resulted in low 
birth weight infants, whereas 148 (10.8%) infants were born pre-
term. Significant differences in birth weight (P = 0.001) and pre-
term birth (P = 0.008) were observed among infants born to women 
with and without these STIs. Low birth weight rates were highest 
among infants born to women with CT and NG (42.9%) compared 
with those born to women with NG only (21.4%), CT only (17.8%) 
and neither CT nor NG (16.9%). Similar differences in death and 
low birth weight rates among these STI groups were noted when 
infants with congenital syphilis were excluded from the analysis.
Infants born to women with CT and NG had the highest 
rates of preterm delivery: 28.6% of infants born to women with CT 
and NG were born preterm in comparison to 10.2% of those born 
to women without CT or NG (P = 0.008). Significant differences 
in infant adverse events were not noted among individual maternal 
STI groups (CT only, NG only, CT and NG and no CT/NG) for 
infants with sepsis, pneumonia, congenital syphilis or septic arthri-
tis. The 2 cases of infant conjunctivitis occurred in women with CT.
Among 1373 infants, 117 (8.5%) were HIV infected. Not 
surprisingly, differences in rates of any of the adverse events 
were noted when comparing HIV-infected (58.1%) versus HIV-
uninfected infants (36.6%; P < 0.0001). Rates of sepsis (12% vs. 
3.3%, P < 0.0001), pneumonia (18.8% vs. 3.7%, P < 0.0001), con-
genital syphilis (10.3% vs. 5.7%, P = 0.05), death (13.7% vs. 2%, 
P < 0.0001) and low birth weight (25.6% vs. 17%, P = 0.02) were 
higher in HIV-infected versus HIV-uninfected infants. Infants who 
had adverse outcomes (Table 2) and were born to women with CT 
and/or NG were 3.5 times more likely to be HIV infected [odds ratio 
(OR): 3.5; 95% confidence interval (CI): 1.4–8.3] after control-
ling for maternal syphilis infection. Similar adjusted associations 
were noted for individual adverse outcomes in infants exposed to 
maternal CT and/or NG and the likelihood of HIV infection: pneu-
monia (OR: 4.7; 95% CI: 1.5–14.9) and death (OR: 6.3; 95% CI: 
1.4–28.1).
In an adjusted multivariate logistic regression controlling for 
infant HIV-infection status, the risk of any adverse infant outcome 
1684 Women Enrolled in NICHD HPTN 040 Parent Study
1406 Maternal Urine Samples Available for Testing
(83.5% of original cohort)
1373 Women and Infants Included in Final 
Analysis  (81.5% of original cohort) 
277 CT or NG or Both CT & NG 
Positive (20.2%) 
249 Any CT Positive (18.1%)
35 CT & NG  
Co-infected (2.5%) 
33 (2.3%) with Indeterminant
Results Excluded
1096 (79.8%) No CT or NG
63 Any NG Positive (4.6%)
FIGURE 1. Flow chart of 
subjects enrolled in the present 
analysis.
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(eg, including sepsis, pneumonia, low birth weight, prematurity and/
or death) in infants born to mothers with CT, NG or both was 1.35 
(OR: 1.35; 95% CI: 1.03–1.76) times more than infants born to moth-
ers without any STI. However, no associations were noted for indi-
vidual infant adverse outcomes and those maternal STIs (Table 3).
DISCUSSION
We evaluated the association of CT and NG infections 
with adverse infant outcomes. We found that infants born to HIV-
infected women with CT and/or NG infection were more likely to 
have an adverse event through age 6 months when compared with 
infants born to HIV-infected women without these STIs. In our 
stratified analysis, the differences for death, low birth weight and 
preterm delivery were most pronounced for those infants born to 
women with dual CT and NG infection.
Death in the first 6 months of life occurred in 11.4% of HIV-
exposed infants born to women with CT and NG dual infection, 
but there was no mortality difference for those with only CT or 
only NG infections when compared with infants of mothers without 
either infection. Congenital syphilis and HIV infection are known 
risk factors for infant death; however, these differences for CT and 
NG coinfection persisted even after controlling for these confound-
ers.9–11 Although limited, the few other existing published studies 
have also suggested that STIs such as CT or NG during pregnancy 
may be associated with increased rates of neonatal and infant 
death.6,12–15 One prior study found that stillbirth or neonatal death 
occurred 10 times more often among CT-infected women than 
uninfected matched controls.13 Another study, which found reduc-
tions in neonatal death with presumptive STI treatment for Tricho-
monas vaginalis, bacterial vaginosis, CT and NG in pregnancy, also 
provides some support for the causal association of maternal STIs 
in pregnancy and increased neonatal death.16
Preterm birth and low birth weight have been attributed to 
many different risk factors.17,18 It is likely that the women in our 
cohort had some degree of baseline risk for these types of out-
comes, particularly given self-reports of high rates of prior preterm 
birth, usage of alcohol, tobacco and illegal substances and lack of 
prenatal care as discussed in our prior analysis.7 Nevertheless, our 
study provides additional support for the deleterious role of STIs 
and adverse birth outcomes such as preterm birth and low birth 
weight. These findings were particularly striking among the women 
infected with both CT and NG, where 42.9% delivered low birth 
weight infants and 28.6% had premature infants. These coinfected 
women also delivered infants with average birth weights that were 
358.2 g less than women uninfected with either of these STIs. Sev-
eral studies apart from ours have previously suggested that STIs in 
pregnancy such as CT and/or NG may also be linked with deliv-
ery of low birth weight and/or premature infants.6,16,19–24 However, 
studies that have focused on treatment of genital infections and/or 
chorioamnionitis have reported conflicting results with respect to 
improvement in birth outcomes with these interventions.6,16,19,24–29
HIV infection during pregnancy, particularly in women with 
lower CD4 T-cell counts, higher serum HIV viral loads and higher pla-
cental HIV viral loads, have also all been associated with an increased 
prevalence of low birth weight and/or premature infants.30–33 Yet, our 
stratified analysis findings demonstrating that women with STIs had 
higher rates of low birth weight and premature infants remained, even 
after controlling for infant HIV status. Those findings were also not 
explained by high rates of untreated maternal syphilis (10%), as they 
persisted in a second analysis controlling for this variable.34
In fact, our findings may actually underestimate the extent 
of this problem because very low birth weight and early premature 
infants were unable to be included; gestational age of ≥32 weeks 
was required for enrollment in the parent study.
TABLE 1. Adverse Infant Outcomes by Sexually Transmitted Infection Status Among Infants Born to HIV-infected 
Pregnant Women
Total  
(N = 1373), n (%)
CT and NG  
(N = 35), n (%)
CT Only  
(N = 214), n (%)
NG Only  
(N = 28), n (%)
No STI  
(N = 1096), n (%) P*
Any of the following adverse infant outcomes
  No 845 (61.5) 12 (34.3) 130 (60.8) 12 (42.9) 691 (63.0) 0.001
  Yes 528 (38.5) 23 (65.7) 84 (39.3) 16 (57.1) 405 (37.0)
Sepsis
  No 1318 (96.0) 33 (94.3) 206 (96.3) 25 (89.3) 1054 (96.2) 0.30
  Yes 55 (4.0) 2 (5.7) 8 (3.7) 3 (10.7) 42 (3.8)
Pneumonia
  No 1305 (95.0) 33 (94.3) 204 (95.3) 24 (85.7) 1044 (95.3) 0.15
  Yes 68 (5.0) 2 (5.7) 10 (4.7) 4 (14.3) 52 (4.7)
Congenital syphilis
  No 1289 (93.9) 32 (91.4) 203 (94.9) 26 (92.9) 1028 (93.8) 0.85
  Yes 84 (6.1) 3 (8.6) 11 (5.1) 2 (7.1) 68 (6.2)
Septic arthritis
  No 1372 (99.9) 35 (100.0) 214 (100.0) 28 (100.0) 1095 (99.9) 0.97
  Yes 1 (0.1) 0 (0.00) 0 (0.00) 0 (0.00) 1 (0.1)
Conjunctivitis
  No 1371 (99.9) 35 (100.0) 212 (99.1) 28 (100.0) 1096 (100.0) 0.01
  Yes 2 (0.1) 0 (0.00) 2 (0.9) 0 (0.00) 0 (0.00)
Death
  No 1332 (97.0) 31 (88.6) 210 (98.1) 28 (100.0) 1063 (97.0) 0.02
  Yes 41 (3.0) 4 (11.4) 4 (1.9) 0 (0.00) 33 (3.0)
Low birth weight
  ≥2500 g 1129 (82.2) 20 (57.1) 176 (82.2) 22 (78.6) 911 (83.1) 0.001
  <2500 g 244 (17.8) 15 (42.9) 38 (17.8) 6 (21.4) 185 (16.9)
Gestational age
  ≥37 wk 1225 (89.2) 25 (71.4) 191 (89.2) 25 (89.3) 984 (89.8) 0.008
  <37 wk 148 (10.8) 10 (28.6) 23 (10.8) 3 (10.7) 112 (10.2)
*P value calculated using χ2 (or Fisher exact) test between groups.
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Adachi et al The Pediatric Infectious Disease Journal • Volume 35, Number 8, August 2016
898 | www.pidj.com © 2016 Wolters Kluwer Health, Inc. All rights reserved.
In our evaluation of the effect of chlamydial and gono-
coccal infections during pregnancy and adverse events among a 
cohort of HIV-exposed infants, it may not be surprising that we 
found high overall rates of adverse outcomes and also signifi-
cant differences in adverse outcome rates when comparing HIV-
infected and HIV-uninfected infants.31,32,35–42 Existing research on 
HIV-exposed infants has suggested that HIV exposure alone may 
be a risk factor for other infections, particularly in infants born to 
women with advanced HIV infection, due to genital colonization 
of pathogens, subclinical chorioamnionitis and lower protective 
antibody titers resulting in decreased transfer of passive immunity 
across the placenta.43 However, while our infant cohort appeared 
to be at risk for adverse outcomes from HIV exposure at baseline, 
we still found that infants born to CT- and/or NG-infected mothers 
were more likely to have an adverse outcome, irrespective of infant 
HIV infection. In our multivariate logistic regression analysis, 
although risk could not be associated with individual adverse out-
comes (likely because of sample size), the risk of any adverse out-
come was 1.36 times more likely in infants of women with CT and/
or NG. When the analysis was adjusted for HIV-infection status, 
the risk of any adverse outcome remained essentially unchanged 
(adjusted OR = 1.35).
One limitation of our study was that the sample size to eval-
uate the impact of STIs on infant outcomes in the first 6 months 
of life was based on convenience. The ability to detect differences 
in adverse infant outcomes by maternal STI group may have been 
limited by the modest sample size, particularly when STI exposures 
were combined with analysis of the infant HIV status. Furthermore, 
TABLE 2. Relationship of Infant HIV Infection Status With Adverse Infant Outcomes Among Infants Born to HIV-infected 
Women With Any Sexually Transmitted Infection (CT/NG Including CT and NG Coinfection)
Total  
(N = 277),  
n (col %)
HIV infected  
(N = 28),  
n (row %)
HIV uninfected  
(N = 249),  
n (row %)
Unadjusted Adjusted*
OR (95% CI) P OR (95% CI) P
Any of the following adverse infant outcomes
  No 154 (55.6) 8 (5.2) 146 (94.8) 1.00 0.004 1.00 0.006
  Yes 123 (44.4) 20 (16.3) 103 (83.7) 3.54 (1.50–8.36) 3.45 (1.43–8.31)
Sepsis
  No 264 (95.3) 26 (9.8) 238 (90.2) 1.00 0.52 1.00 0.60
  Yes 13 (4.7) 2 (15.4) 11 (84.6) 1.66 (0.35–7.92) 1.52 (0.31–7.40)
Pneumonia
  No 261 (94.2) 23 (8.8) 238 (91.2) 1.00 0.008 1.00 0.008
  Yes 16 (5.8) 5 (31.3) 11 (68.8) 4.70 (1.50–14.72) 4.74 (1.51–14.90)
Congenital syphilis
  No 261 (94.2) 25 (9.6) 236 (90.4) 1.00 0.25
  Yes 16 (5.8) 3 (18.8) 13 (81.3) 2.18 (0.58–8.17)
Septic arthritis
  No 277 (100) 28 (10.1) 249 (89.9)
  Yes 0 (0.0) 0 (0.0) 0 (0.0)
Conjunctivitis
  No 275 (99.3) 28 (10.2) 247 (89.8) 1.00 1.0 1.00 1.0
  Yes 2 (0.7) 0 (0.0) 2 (100) 3.69 (0–31.24) 3.92 (0–33.21)
Death
  No 269 (97.1) 25 (9.3) 244 (90.7) 1.00 0.02 1.00 0.016
  Yes 8 (2.9) 3 (37.5) 5 (62.5) 5.86 (1.32–25.97) 6.30 (1.41–28.14)
Low birth weight
≥2500 g 218 (78.7) 22 (10.1) 196 (89.9) 1.00 0.99 1.00 0.92
<2500 g 59 (21.3) 6 (10.2) 53 (89.8) 1.01 (0.39–2.61) 0.95 (0.36–2.50)
Gestational age
  ≥37 wk 241 (87.0) 22 (9.1) 219 (90.9) 1.00 0.17 1.00 0.15
  <37 wk 36 (13.0) 6 (16.7) 30 (83.3) 1.99 (0.75–5.30) 2.08 (0.77–5.57)
OR calculated by univariate or exact logistic regression as necessary.
*Each adverse infant outcome was adjusted for maternal syphilis status using multivariable logistic regression.
TABLE 3. Relationship of CT/NG With Adverse Infant Outcomes With/Without Adjusting for 
Infant HIV Infection Status
Adverse Infant Outcomes
Unadjusted  
(Predictor = Any CT/NG)
After Adjusting for HIV status  
(Predictor = Any CT/NG + HIV Status)
OR (95% CI) P OR (95% CI) P
Any adverse infant outcomes (yes) 1.36 (1.04–1.78) 0.02 1.35 (1.03–1.76) 0.03
Sepsis (yes) 1.24 (0.65–2.34) 0.51 1.19 (0.62–2.26) 0.60
Pneumonia (yes) 1.23 (0.69–2.19) 0.48 1.16 (0.65–2.10) 0.61
Low birth weight <2500 g 1.33 (0.96–1.85) 0.086 1.32 (0.95–1.83) 0.099
Gestational age <37 wk 1.31 (0.88–1.96) 0.18 1.31 (0.87–1.95) 0.19
Death (yes) 0.96 (0.44–2.10) 0.91 0.88 (0.40–1.96) 0.76
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although data were collected on all types of serious adverse events 
and clinical outcomes that occurred in the parent study, our analysis 
was limited to adverse infant outcomes that were more frequently 
reported with CT and/or NG infections as opposed to other non-
specific adverse outcomes such as respiratory distress, hypoglyce-
mia, neutropenia, thrombocytopenia and gastroenteritis that were 
not included. These other types of adverse outcomes have been 
reported in a separate analysis of a cohort of 1000 HIV-exposed 
uninfected infants in NICHD HPTN 040.44
CONCLUSION
This study provides important information about the poten-
tial deleterious effects of untreated maternal STIs such as CT and 
NG on the well-being of infants born to high-risk groups of HIV-
infected women in low- and middle-income countries. The combi-
nation of untreated CT and/or NG infection in pregnancy and HIV 
exposure appears to increase the likelihood of adverse outcomes in 
these infants beyond the risk of HIV acquisition. This additional 
substudy again highlights the potential benefits of prenatal labora-
tory-based STI screening and treatment programs, particularly for 
high risk groups such as HIV-infected pregnant women, which may 
aid in preventing these types of adverse infant outcomes.
ACKNOWLEDGMENTS
Kristina Adachi drafted the initial substudy design and data 
analysis, drafted the initial manuscript and revised and approved the 
final manuscript as submitted. Jeffrey D. Klausner provided over-
sight for the current substudy design, data analysis, reviewed, revised 
and approved final manuscript as submitted. Jiahong Xu designed 
the data collection instruments, organized data entry for the initial 
study, provided methods for data analysis, confirmed and finalized 
primary data analysis study results presented in this paper. Bonnie 
Ank assisted with preparation and coordination of urine samples 
from study sites to Cepheid, Inc. and provided laboratory support in 
the US. Claire C. Bristow performed some of the preliminary data 
analysis, reviewed and revised the manuscript and approved the 
final manuscript as submitted. Fred Weir provided direct oversight 
of specimen analysis at Cepheid with the Xpert CT/NG assay. David 
Persing facilitated specimen analysis at Cepheid. Mariza Morgado 
provided laboratory support in Brazil for study conduct, specimen 
storage, transfer of specimens to the US and participated in data 
analysis. Esau Joao, Jose Henrique Pilotto, Glenda Gray, Gerhard 
Theron, Breno Santos, Rosana Fonseca, Regis Kreitchmann, Jorge 
Pinto, Marisa M. Mussi-Pinhata, Mariana Ceriotto, Daisy Machado, 
Beatriz Grinsztejn and Francisco I. Bastos were responsible for ini-
tial study design, patient recruitment and patient care enrolled in this 
study at sites in Brazil and in South Africa. They also reviewed and 
revised the manuscript and approved the final manuscript as sub-
mitted. D. Heather Watts, Valdilea Veloso, Lynne Mofenson, Yvonne 
Bryson, George Siberry and Karin Nielsen-Saines supervised the 
design of the data collection instruments, supervised data collection 
at all sites, critically reviewed the manuscript and approved the final 
manuscript as submitted. Dr. Nielsen-Saines was the principal inves-
tigator of the parent study as well as this current substudy.
The authors thank the patients and their families who 
enrolled in this trial. The authors thank two laboratory personnel 
who conducted all of the urine specimen preparation and shipment, 
Mary Ann Hausner and Jessica Liu. The authors also thank Marita 
McDonough and Lauren Petrella from Boehringer Ingelheim Phar-
maceuticals and Helen Watson from GlaxoSmithKline (on behalf 
of ViiV Healthcare) for assistance with the donation of study drugs 
from their respective companies for the conduct of the parent study.
In addition to the authors, members of the National Insti-
tute of Child Health and Human Development HIV Prevention 
Trials Network 040/PACTG 1043 protocol team include the fol-
lowing: Edgardo Szyld and Silvia Marzo, Buenos Aires-Founda-
tion for Maternal and Infant Health, Argentina; Flavia Faleiro 
Ferreira and Fabiana Kakehasi, Belo Horizonte-Federal Uni-
versity of Minas Gerais, Brazil; Rita Lira, Porto Alegre-Hospital 
Nossa Senhora da Conceicao; Carla Franceschini de Fraga Rita 
Lira, Porto Alegre-Hospital Femina; Debora Fernandes Coelho, 
Alberto Sanseverino and Luis Carlos Ribeiro, Porto Alegre-Irman-
dade da Santa Casa de Misericordia de Porto Alegre; M. Leticia 
Santos Cruz, Ezequias Martins, Jacqueline Anita de Menezes and 
Luisa Andrea Torres Salgado, Rio de Janeiro-Hospital dos Servi-
dores do Estado; Ana Valeria Cordovil, Andréa Gouveia, Priscila 
Mazzucanti and Jorge Eurico Ribeiro, Rio de Janeiro-Hospital 
Geral de Nova Iguaçu; Geraldo Duarte, Adriana Aparecida Tira-
boschi Barbaro and Carolina Sales Vieira, Ribeirao Preto-Uni-
versidade de Sao Paulo; Regina Succi, Sao Paulo-Universidade 
Federal de Sao Paulo; Mark Cotton, Jeanne Louw and Elke Mar-
itz, Capetown-Stellenbosch University and Tygerberg Hospital, 
South Africa; Sarita Lalsab, Shini Legoete, James Alasdair McI-
ntyre and Mandisa Nyati, Johannesburg-Perinatal HIV Research 
Unit, University of Witwatersrand and Chris Hani Baragwanath 
Hospital; Allison Agwu, Jean Anderson, Joan Bess, Jonathan 
Ellen, Todd Noletto and Nancy Hutton, Baltimore-Johns Hop-
kins University; Carol Delany and Robert M. Lawrence, Gaines-
ville-Shands Hospital; Chas Griggs, Mobeen Rathore, Kathleen 
Thoma and Michelle Tucker, Jacksonville-University of Florida; 
Audra Deveikis and Susan Marks, Long Beach-Miller Childrens 
Hospital; Linda Bettica, James M. Oleske, Newark-University 
Medical and Dental School of New Jersey; Midnela Acevedo Flo-
res and Elvia Pérez, San Juan City-San Juan City Hospital; Ron-
aldo I. Moreira, Marilia Santini de Oliveira, Monica Derrico, 
Valéria Ribeiro and Thiago Torres, FIOTEC (Fundação para o 
Desenvolvimento Científico e Tecnológico), Oswaldo Cruz Foun-
dation, Rio de Janeiro (FIOCRUZ); Ruth Dickover, University of 
California-Davis; Mark Mirochnick, Boston University; Marga-
ret Camarca, James Bethel, Emmanuel Aluko, Yolanda Bertucci, 
Jennifer Bryant, Patty Chen, Barbara Driver, Ruby Duston, Adri-
ana Ferreira, Priya Guyadeen, Sarah Howell, Marsha Johnson, 
Linda Kaufman, Naomi Leshabane, Lilya Meyerson, Rita Patel, 
Lubima Petrova, Georgine Price, Susan Raitt, Scott Watson, Yil-
ing Xu and Eunice Yu, Westat, Inc. Other protocol team members 
included, Jennifer Read and Jack Moye from the Eunice Kennedy 
Shriver National Institute of Child Health and Human Develop-
ment and Elizabeth Smith and Sheryl Zwerski from the National 
Institute of Allergy and Infectious Diseases.
REFERENCES
 1. World Health Organization. Global Incidence and Prevalence of Selected 
Curable Sexually Transmitted Infections 2008. Geneva, Switzerland: World 
Health Organization; 2012.
 2. Silveira MF, Ghanem KG, Erbelding EJ, et al. Chlamydia trachomatis infec-
tion during pregnancy and the risk of preterm birth: a case-control study. Int 
J STD AIDS. 2009;20:465–469.
 3. Woods CR. Gonococcal infections in neonates and young children. Semin 
Pediatr Infect Dis. 2005;16:258–270.
 4. Hammerschlag MR. Chlamydial and gonococcal infections in infants and 
children. Clin Infect Dis. 2011;53(suppl 3):S99–S102.
 5. World Health Organization. Global Strategy for Prevention and Control of 
Sexually Transmitted Infections: 2006–2105. Geneva, Switzerland: World 
Health Organization; 2006.
 6. Silva MJ, Florêncio GL, Gabiatti JR, et al. Perinatal morbidity and mortality 
associated with chlamydial infection: a meta-analysis study. Braz J Infect 
Dis. 2011;15:533–539.
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Adachi et al The Pediatric Infectious Disease Journal • Volume 35, Number 8, August 2016
900 | www.pidj.com © 2016 Wolters Kluwer Health, Inc. All rights reserved.
 7. Adachi K, Klausner JD, Bristow CC, et al; NICHD HPTN 040 Study Team. 
Chlamydia and gonorrhea in HIV-infected pregnant women and infant HIV 
transmission. Sex Transm Dis. 2015;42:554–565.
 8. Nielsen-Saines K, Watts DH, Veloso VG, et al; NICHD HPTN 040/PACTG 
1043 Protocol Team. Three postpartum antiretroviral regimens to prevent 
intrapartum HIV infection. N Engl J Med. 2012;366:2368–2379.
 9. Gomez GB, Kamb ML, Newman LM, et al. Untreated maternal syphilis and 
adverse outcomes of pregnancy: a systematic review and meta-analysis. Bull 
World Health Organ. 2013;91:217–226.
 10. Kuznik A, Habib AG, Manabe YC, et al. Estimating the public health burden 
associated with adverse pregnancy outcomes resulting from syphilis infection 
across 43 countries in Sub-Saharan Africa. Sex Transm Dis. 2015;42:369–375.
 11. Kapogiannis BG, Soe MM, Nesheim SR, et al. Mortality trends in the US 
perinatal AIDS collaborative transmission study (1986–2004). Clin Infect 
Dis. 2011;53:1024–1034.
 12. Gencay M, Koskiniemi M, Saikku P, et al. Chlamydia trachomatis sero-
positivity during pregnancy is associated with perinatal complications. Clin 
Infect Dis. 1995;21:424–426.
 13. Martin DH, Koutsky L, Eschenbach DA, et al. Prematurity and perinatal 
mortality in pregnancies complicated by maternal Chlamydia trachomatis 
infections. JAMA. 1982;247:1585–1588.
 14. Panaretto KS, Lee HM, Mitchell MR, et al. Prevalence of sexually transmitted 
infections in pregnant urban Aboriginal and Torres Strait Islander women in 
northern Australia. Aust N Z J Obstet Gynaecol. 2006;46:217–224.
 15. Bouwhuis SA, Davis MD. Contribution of sexually transmitted diseases and 
socioeconomic factors to perinatal mortality in rural Ghana. Int J Dermatol. 
2004;43:27–30.
 16. Gray RH, Wabwire-Mangen F, Kigozi G, et al. Randomized trial of pre-
sumptive sexually transmitted disease therapy during pregnancy in Rakai, 
Uganda. Am J Obstet Gynecol. 2001;185:1209–1217.
 17. March of Dimes P, Save the Children, World Health Organization. Born Too 
Soon: The Global Action Report on Preterm Birth. Geneva, Switzerland: 
World Health Organization, 2012.
 18. Lawn JE, Gravett MG, Nunes TM, et al. Global report on preterm birth and 
stillbirth (1 of 7): definitions, description of the burden and opportunities to 
improve data. BMC pregnancy and childbirth. 2010;10(suppl 1):S1.
 19. Goldenberg RL, Mudenda V, Read JS, et al. HPTN 024 study: histo-
logic chorioamnionitis, antibiotics and adverse infant outcomes in a pre-
dominantly HIV-1-infected African population. Am J Obstet Gynecol. 
2006;195:1065–1074.
 20. Donders GG, Desmyter J, De Wet DH, et al. The association of gonorrhoea 
and syphilis with premature birth and low birthweight. Genitourin Med. 
1993;69:98–101.
 21. Andrews WW, Goldenberg RL, Mercer B, et al. The preterm prediction study: 
association of second-trimester genitourinary chlamydia infection with subse-
quent spontaneous preterm birth. Am J Obstet Gynecol. 2000;183:662–668.
 22. Kovács L, Nagy E, Berbik I, et al. The frequency and the role of Chlamydia tra-
chomatis infection in premature labor. Int J Gynaecol Obstet. 1998;62:47–54.
 23. Blas MM, Canchihuaman FA, Alva IE, et al. Pregnancy outcomes in women 
infected with Chlamydia trachomatis: a population-based cohort study in 
Washington State. Sex Transm Infect. 2007;83:314–318.
 24. Goldenberg RL, Mwatha A, Read JS, et al; Hptn024 Team. The HPTN 024 
study: the efficacy of antibiotics to prevent chorioamnionitis and preterm 
birth. Am J Obstet Gynecol. 2006;194:650–661.
 25. Martin DH, Eschenbach DA, Cotch MF, et al. Double-blind placebo-con-
trolled treatment trial of Chlamydia trachomatis endocervical infections in 
pregnant women. Infect Dis Obstet Gynecol. 1997;5:10–17.
 26. Cohen I, Veille JC, Calkins BM. Improved pregnancy outcome 
following successful treatment of chlamydial infection. JAMA. 
1990;263:3160–3163.
 27. Ryan GM Jr, Abdella TN, McNeeley SG, et al. Chlamydia trachomatis 
infection in pregnancy and effect of treatment on outcome. Am J Obstet 
Gynecol. 1990;162:34–39.
 28. McGregor JA, French JI, Richter R, et al. Cervicovaginal microflora and 
pregnancy outcome: results of a double-blind, placebo-controlled trial of 
erythromycin treatment. Am J Obstet Gynecol. 1990;163(5 pt 1):1580–1591.
 29. Andrews WW, Klebanoff MA, Thom EA, et al. Midpregnancy genitouri-
nary tract infection with Chlamydia trachomatis: association with subse-
quent preterm delivery in women with bacterial vaginosis and Trichomonas 
vaginalis. Am J Obstet Gynecol. 2006;194:493–500.
 30. Turner AN, Tabbah S, Mwapasa V, et al. Severity of maternal HIV-1 disease 
is associated with adverse birth outcomes in Malawian women: a cohort 
study. J Acquir Immune Defic Syndr. 2013;64:392–399.
 31. Brocklehurst P, French R. The association between maternal HIV infection 
and perinatal outcome: a systematic review of the literature and meta-analy-
sis. Br J Obstet Gynaecol. 1998;105:836–848.
 32. Kim HY, Kasonde P, Mwiya M, et al. Pregnancy loss and role of infant HIV 
status on perinatal mortality among HIV-infected women. BMC Pediatr. 
2012;12:138.
 33. Marazzi MC, Palombi L, Nielsen-Saines K, et al. Extended antenatal use of triple 
antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 
correlates with favorable pregnancy outcomes. AIDS. 2011;25:1611–1618.
 34. Yeganeh N, Watts HD, Camarca M, et al; NICHD HPTN 040P1043 Study 
Team. Syphilis in HIV-infected mothers and infants: results from the 
NICHD/HPTN 040 study. Pediatr Infect Dis J. 2015;34:e52–e57.
 35. Nielsen-Saines K, Komarow L, Cu-Uvin S, et al; ACTG 5190/PACTG 
1054 Study Team. Infant outcomes after maternal antiretroviral exposure in 
resource-limited settings. Pediatrics. 2012;129:e1525–e1532.
 36. Owor M, Mwatha A, Donnell D, et al. Long-term follow-up of children in 
the HIVNET 012 perinatal HIV prevention trial: five-year growth and sur-
vival. J Acquir Immune Defic Syndr. 2013;64:464–471.
 37. Newell ML, Borja MC, Peckham C; European Collaborative Study. Height, 
weight, and growth in children born to mothers with HIV-1 infection in 
Europe. Pediatrics. 2003;111:e52–e60.
 38. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and 
adverse birth outcomes among HIV-infected women in Botswana. J Infect 
Dis. 2012;206:1695–1705.
 39. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al. Mortality in HIV-
infected and uninfected children of HIV-infected and uninfected mothers in 
rural Uganda. J Acquir Immune Defic Syndr. 2006;41:504–508.
 40. Koyanagi A, Humphrey JH, Ntozini R, et al; ZVITAMBO Study Group. 
Morbidity among human immunodeficiency virus-exposed but uninfected, 
human immunodeficiency virus-infected, and human immunodeficiency 
virus-unexposed infants in Zimbabwe before availability of highly active 
antiretroviral therapy. Pediatr Infect Dis J. 2011;30:45–51.
 41. Kourtis AP, Wiener J, Kayira D, et al. Health outcomes of HIV-exposed 
uninfected African infants. AIDS. 2013;27:749–759.
 42. Rollins NC, Coovadia HM, Bland RM, et al. Pregnancy outcomes in HIV-
infected and uninfected women in rural and urban South Africa. J Acquir 
Immune Defic Syndr. 2007;44:321–328.
 43. Mussi-Pinhata MM, Freimanis L, Yamamoto AY, et al; National Institute of 
Child Health and Human Development International Site Development Initiative 
Perinatal Study Group. Infectious disease morbidity among young HIV-1-
exposed but uninfected infants in Latin American and Caribbean countries: the 
National Institute of Child Health and Human Development International Site 
Development Initiative Perinatal Study. Pediatrics. 2007;119:e694–e704.
 44. Nielsen-Saines K, Watts DH, Joao EC, et al; the NICHD HPTN 040/ 
PACTG 1043 Protocol Team. To formula feed or not: Infectious morbid-
ity, mortality and growth of HIV-exposed, uninfected, formula-fed infants in 
Brazil and South Africa enrolled in NICHD/HPTN 040/PACTG 1043. 3rd 
Pediatrics HIV Conference. Rome, Italy. 2011.
